SCHEMBL7219705

SCHEMBL7219705

Cc1ccc(C2CNC(=O)OC23CCN(C(=O)c2cc(C(F)(F)F)cc(C(F)(F)F)c2)CC3)cc1C

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 4/20 0.46
TSHR P16473 9/20 0.43
CYP3A4 P08684 8/20 0.43
CYP2D6 P10635 5/20 0.43
CYP1A2 P05177 3/20 0.43
CYP2C9 P11712 8/20 0.43
TACR1 P25103 2/20 0.42
USP2 O75604 10/20 0.42
CYP2C19 P33261 3/20 0.42
PLD2 O14939 1/20 0.42
PLD1 Q13393 1/20 0.42
HSD17B10 Q99714 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7219708 1.00 HIF1A (0.46) HIF1ATSHRCYP3A4CYP2D6CYP1A2
SCHEMBL5010895 0.88 TSHR (0.46) HIF1ATSHRCYP3A4CYP2D6CYP1A2
SCHEMBL5012597 0.88 TSHR (0.46) HIF1ATSHRCYP3A4CYP2D6CYP1A2
SCHEMBL5012659 0.87 USP2 (0.43) HIF1ATSHRCYP3A4CYP2D6CYP1A2
SCHEMBL5012620 0.87 USP2 (0.43) HIF1ATSHRCYP3A4CYP2D6CYP1A2
SCHEMBL7109251 0.87 RHOC (0.49) HIF1ATSHRCYP3A4CYP2D6CYP1A2
SCHEMBL7109255 0.87 RHOC (0.49) HIF1ATSHRCYP3A4CYP2D6CYP1A2
SCHEMBL5012152 0.87 CYP3A4 (0.53) HIF1ATSHRCYP3A4CYP2D6CYP1A2
SCHEMBL5010920 0.87 CYP3A4 (0.53) HIF1ATSHRCYP3A4CYP2D6CYP1A2
SCHEMBL7220619 0.85 TSHR (0.47) HIF1ATSHRCYP3A4CYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599900-B2 Antiinflammatory agents; headaches; antiarthritic agents SYNTEX (U.S.A.) LLC 2003-07-29 US disclosed
US-20030004163-A1 1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones SYNTEX (U.S.A) LLC 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004163-A1 1-Oxa-3,9-diaza-spiro[5,5]undecan-2-ones OXER1, NR4A1, OXGR1 HIF1A 1257/4885TSHR 298/4885CYP3A4 1472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.